Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Clinical heterogeneity and some clinical and genetic variants of inflammatory bowel diseases
https://doi.org/10.33667/2078-5631-2025-6-25-28
Abstract
The study of inflammatory bowel diseases is characterized by dynamism and new discoveries. The desire for personalized therapy for this category of patients urgently dictates the need to decipher the genetic architecture of ulcerative colitis and Crohn's disease. The completion of the human genome project was marked by the discovery of more than 240 genetic polymorphisms in inflammatory bowel diseases. Comparison of clinical and genetic features confirmed the existence of various clinical and genetic phenotypes of ulcerative colitis and Crohn's disease, many risk options and shed light on key pathogenetic mechanisms. These include mechanisms of breakdowns in the innate immune system and autophagy processes, impaired lymphocyte differentiation and chemotaxis. The introduction of these provisions into clinical practice will not only improve the diagnostic process, but will also significantly contribute to personalized therapy.
About the Authors
A. M. Pershko
Physicians Military Medical Academy named after S. M. Kirov
Russian Federation
Russian Federation
Pershko Anatoliy M., DM Sci (habil.), gastroenterologist, associate professor at the 2nd Dept of Advanced Medical Training of Physicians,
St. Petersburg.
G. I. Ismailova
Physicians Military Medical Academy named after S. M. Kirov
Russian Federation
Russian Federation
Ismailova Gunay I., 2nd year Clinical Resident in the Specialty Gastroenterology,
St. Petersburg.
References
1. Cleynen I., Boucher G., Jostins L. et al. International Inflammatory Bowel Disease Genetics Consortium. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016; 387: 156–167. https://doi.org/10.1016/S0140–6736(15)00465-1
2. Grinevich V. B., Pershko A. M., Volga N. B., Ivanyuk E. S., Seliverstov P. V. Topical issues of therapy for patients with ulcerative colitis. Meditsinskiy sovet = Medical Council. 2023; 23: 149–154. (In Russ.). https://doi.org/10.21518/ms2023–481
3. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD 2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001 May 31; (411): 599–603. https://doi.org/10.1038/35079107
4. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD 2 associated with susceptibility to Crohn's disease. Nature. 2001; 31. 411(6837): 603–6. https://doi.org/10.1038/35079114
5. Wehkamp J, Fellermann K, Stange EF. Human defensins in Crohn's disease.// Chem Immunol Allergy. 2005; 86: 42–54. https://doi.org/10.1159/000086672
6. Lapaquette P, Thi Thu Nguyen H, Faure M. L’autophagie garante de l’immunité et de l’inflammation. Médecine. Sciences. 2017; 33: 305–311. https://doi.org/10.1051/medsci/20173303018
7. Nguyen HTT, Lapaquette P, Bringer M-A, et al. Autophagy and crohn’s disease. //J Innate Immun. [Internet]. 2013; 5: 434–443. https://doi.org/10.1159/000345129
8. Dumortier J, Lapalus M-G, Guillaud O, et al. Everolimus for refractory Crohn’s disease: a case report. Inflamm Bowel Dis. 2008; 14: 874–877. https://doi.org/10.1002/ibd.20395
9. Massey DCO, Bredin F, Parkes M. Use of sirolimus (rapamycin) to treat refractory Crohn’s disease. Gut. 2008; 57: 294–1296. https://doi.org/10.1136/gut.2008.15729
10. Hansen G, Hercus TR, McClure BJ, et al. The structure of the GM–CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell. 2008; 134: 496–507. https://doi.org/10.1016/j.cell.2008.05.053
11. Burbelo PD, Browne SK, Sampaio EP, et al. Anti-cytokine autoantibodies are as-sociated with opportunistic infection in patients with thymic neoplasia. Blood. 2010; 116: 4848–58. https://doi.org/10.1182/blood-2010-05-286161
12. Karner J, Meager A, Laan M, et al. Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice. Clin. Exp. Immunol. 2013; 171: 263–72. https://doi.org/10.1111/cei.12024
13. Fukuzawa H, Sawada M, Kayahara T, et al. Identification of GM–CSF in Paneth cells using single-cell RT-PCR. Biochem Biophys Res Commun. 2003; 312: 897–902. https://doi. org/10.1016/j.bbrc.2003.11.009
14. Uchida K, Nakata K, Suzuki T, et al. Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood. 2009; 113: 2547–56. https://doi.org/10.1182/blood-2009-05-155689
15. Denson LA, Jurickova I, Karns R, et al. Genetic and transcriptomic variation linked to neutrophil granulocyte-macrophage colony-stimulating factor signaling in pediatric crohn's disease. Inflamm Bowel Dis. 2018; 2018: 265. https://doi.org/10.1093/ibd/izy265
16. Han X., Uchida K., Jurickova I. et al. Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology. 2009; 136: 1261–71. https://doi.org/10.1053/j.gastro.2008.12.046
17. Nylund C. M. et al. Granulocyte macrophage-colony-stimulating factor autoantibodies and increased intestinal permeability in Crohn disease. J. Pediatr. Gastroenterol. Nutr. 2011; 52, (5): 542–8. https://doi.org/10.1097/MPG.0b013e3181fe2d93
18. Wright S. W., Trauernicht A., Bonkowski E. et al. Familial Association of Granulocyte-Macrophage Colony Stimulating Factor Autoantibodies in Inflammatory Bowel Disease. J. Pediatr. Gastroenterol. Nutr. 2018; 66 (5): 767–772. https://doi.org/10.1097/MPG.0000000000001851
19. Bousfiha A, Jeddane L, Picard C. et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2018; 38: 129–143. https://doi.org/10.1007/s10875-017-0465-8
20. Pazmandi J., Kalinichenko A., Ardy R. Ch., Boztug K. Early-onset inflammatory bowel disease as a model disease to indentify key regulators of immune homeostasis mechanisms. Immunological Reviews. 2019; 287 (1). https://doi.org/10.1111/imr.12726
Review
For citations:
Pershko A.M., Ismailova G.I. Clinical heterogeneity and some clinical and genetic variants of inflammatory bowel diseases. Medical alphabet. 2025;(6):25-28. (In Russ.) https://doi.org/10.33667/2078-5631-2025-6-25-28
Views:
58
Email this article 